Tirzepatide Research: Beyond Mounjaro — Dual Agonist Deep Dive
GIP + GLP-1 Mechanism
Metabolic Research
Prescription-Only Research
Last Updated: May 2026
⚠ Prescription-only medication in many jurisdictions. For research purposes only. Not for human consumption.
Tirzepatide — the molecule marketed as Mounjaro (and Zepbound in the US) — is the first dual GIP/GLP-1 receptor agonist to complete a large-scale Phase III clinical trial programme, and the mechanistic depth behind that designation runs considerably further than the surface-level coverage most research summaries provide. This article is not a repeat of the basics. It goes deeper: into the structural biology of the GIP receptor, the nuanced pharmacology that makes dual agonism mechanistically distinct from GLP-1 monotherapy, the paradox embedded in GIP’s role in adipose tissue, the “twincretin” concept as it appears in academic literature, the full SURPASS and SURMOUNT trial architecture, and how tirzepatide compares both to semaglutide (GLP-1 mono-agonist) and to retatrutide (triple GIP/GLP-1/glucagon receptor agonist).
For researchers who have read the foundational overview and want to understand the actual biology — the GIP receptor signalling cascade, what happens when both GIPR and GLP-1R are co-activated simultaneously at the same cell, and how the SURPASS-2 head-to-head against semaglutide should be mechanistically interpreted — this is that article.
Tirzepatide (Mounjaro) is a prescription-only medicine (POM) in the UK under the Human Medicines Regulations 2012. Pure Grade Labs supplies it strictly as a research chemical for laboratory purposes only — not for human consumption or any therapeutic application. All clinical trial data cited here is referenced as published scientific record for mechanistic research context only.
Key Takeaways
- POM status — research context only: Tirzepatide is a prescription-only medicine in the UK (HMR 2012) and most other jurisdictions. Pure Grade Labs supplies it as a research chemical only — not for human use. All content in this article is for mechanistic research context.
- Dual agonism is not additive — it is interactive: GIPR and GLP-1R co-activation does not simply sum the effects of each receptor. Published research has characterised the interaction as producing complementary intracellular signalling that differs qualitatively from either receptor in isolation — a key mechanistic distinction for research design.
- The GIP receptor paradox: Endogenous GIP was classically characterised as adipogenic (promoting fat storage). In the context of dual GIPR/GLP-1R co-activation, the adipose tissue signalling picture is more complex — a context-dependent receptor response that is one of the most actively investigated questions in dual agonism research (Samms RJ et al. 2021, Cell Metabolism).
- SURMOUNT-1 (2022) trial facts: 2,539 participants, 72 weeks, published in the New England Journal of Medicine (Jastreboff AM et al.) — the largest body composition research dataset for a dual incretin agonist at the time of publication.
- Where tirzepatide sits on the incretin agonism spectrum: Semaglutide (GLP-1 mono) → Tirzepatide (GIP + GLP-1 dual) → Retatrutide (GIP + GLP-1 + GCGR triple). Each step adds a receptor target and a corresponding mechanistic research dimension.
Molecular weight of tirzepatide — a 39 amino acid dual GIP/GLP-1 receptor agonist with C20 fatty diacid albumin-binding moiety
Participants in SURMOUNT-1 (2022) — 72 weeks, body composition research cohort, no T2D (Jastreboff AM et al., NEJM)
Ki binding range — tirzepatide is equipotent at GIPR and GLP-1R in cell-based cAMP assays (Willard FS et al. 2020, JCI Insight)
Participants in SURPASS-2 — tirzepatide vs semaglutide 1mg head-to-head, 40 weeks (Frias JP et al. 2021, NEJM)
What Is Tirzepatide? Formal Structure and the Twincretin Design
Tirzepatide (CAS: 2023788-19-2) is a synthetic 39-amino-acid peptide developed by Eli Lilly and Company. Its molecular weight is 4813.5 Da. The backbone of the molecule is based on the native GIP (glucose-dependent insulinotropic polypeptide) peptide sequence — not GLP-1, as is sometimes assumed. This matters for understanding its receptor bias: tirzepatide was engineered from the GIP scaffold, which is why it has full agonist activity at GIPR and partial agonist activity at GLP-1R, rather than the reverse.
The molecule’s extended half-life — approximately five days in vivo — is achieved through a C20 fatty diacid moiety attached via a linker to the peptide backbone. This fatty acid modification enables non-covalent, reversible albumin binding in plasma. Only the unbound fraction is pharmacologically active at any given time, with the albumin-bound pool acting as a slow-release reservoir that sustains effective plasma concentrations over weekly administration intervals. This is the same engineering principle used for semaglutide’s C18 fatty acid albumin binding — but the longer C20 diacid chain in tirzepatide contributes to subtly different binding kinetics.
The term “twincretin” emerged in academic literature to describe tirzepatide’s fundamental design concept — a single unimolecular entity that mimics two distinct incretin hormones simultaneously. Incretins are gut-derived hormones that augment insulin secretion in response to nutrient ingestion. GLP-1 and GIP are the two principal incretin hormones in humans, and they act through distinct but partially overlapping receptor systems. Tirzepatide was designed to co-activate both with a single injection — the first pharmaceutical molecule to achieve this in a Phase III clinical trial setting.
DPP-4 Resistance Mechanism
Both native GLP-1 and native GIP are rapidly degraded by dipeptidyl peptidase-4 (DPP-4), an enzyme that cleaves the penultimate N-terminal residue from peptide substrates with a penultimate alanine or proline. Native GIP is also a DPP-4 substrate, with a plasma half-life of approximately 7 minutes in vivo. Tirzepatide circumvents this via alpha-aminoisobutyric acid (Aib) substitution at position 2 — introducing steric bulk that prevents DPP-4 from accessing the cleavage site. The combination of DPP-4 resistance at the N-terminus and albumin-mediated half-life extension at the C-terminal fatty acid moiety produces the observed ~5-day half-life, enabling a research-relevant pharmacokinetic profile for weekly experimental intervals.
The GIP Receptor: Structure, Distribution, and Signalling Cascade
The GIP receptor (GIPR) is a class B1 G protein-coupled receptor (GPCR) — the same structural family as the GLP-1R, glucagon receptor (GCGR), and PTH1 receptor. Class B1 GPCRs are characterised by a large extracellular N-terminal domain (ECD) that forms a binding cleft for the C-terminal region of their peptide ligands, and a transmembrane bundle domain that engages the N-terminal portion of the ligand and facilitates intracellular G protein coupling. The two-domain binding mechanism (sometimes called the “two-site” or “address-message” model) is mechanistically important: it means that partial agonists at class B GPCRs can engage one domain without the other, producing distinct downstream signalling profiles from full agonists — a nuance relevant to tirzepatide’s characterisation as a biased agonist.
GIPR Tissue Distribution
One of the most important reasons the GIP receptor is mechanistically interesting for metabolic research is the breadth of its tissue distribution — which is substantially wider than GLP-1R in several key compartments:
- Pancreatic beta cells: GIPR is expressed alongside GLP-1R on beta cells. Both receptors couple to Gs and elevate intracellular cAMP, activating PKA and EPAC2 to potentiate glucose-stimulated insulin secretion (GSIS). The two receptors use overlapping but non-identical downstream substrates within the same cell — published research has proposed that co-activation may produce non-redundant or complementary amplification of the GSIS signal (Willard FS et al. 2020, JCI Insight).
- Adipose tissue: GIPR is abundantly expressed in adipocytes and adipose stromal vascular fraction cells. GLP-1R expression in white adipose tissue is minimal by comparison. This creates an adipose tissue GIPR signalling dimension in tirzepatide research that is entirely absent from semaglutide research models — a fundamentally different peripheral pharmacology at the tissue level.
- Bone: GIPR expression on osteoblasts and osteoclasts has been documented in multiple species. Rodent knockout models lacking GIPR show reduced bone mineral density and altered bone turnover markers (Zhong Q et al. 2007, Am J Physiol Endocrinol Metab). This represents a unique research angle for tirzepatide in bone biology studies — one for which semaglutide has no mechanistic equivalent.
- Brain / Central Nervous System: GIPR is expressed in hypothalamic regions including the arcuate nucleus and paraventricular nucleus — areas with well-documented roles in energy balance, appetite regulation, and neuroendocrine integration. The relative contributions of hypothalamic GIPR versus GLP-1R activation to tirzepatide’s central signalling profile remain an active research question, with published preclinical data suggesting complementary rather than redundant central mechanisms.
- Cardiac tissue: GIPR expression has been documented in cardiac myocytes. Published research has investigated GIPR-mediated cardiac effects independently of GLP-1R. The cardiovascular research implications of GIPR co-activation are one rationale for the SURPASS-CVOT trial design.
GIPR Intracellular Signalling Cascade
When tirzepatide (or endogenous GIP) engages GIPR, the receptor undergoes conformational activation and couples primarily to the stimulatory G protein subunit Gαs. Activated Gαs stimulates membrane-bound adenylyl cyclase (AC), driving conversion of ATP to cyclic AMP (cAMP). Elevated intracellular cAMP then bifurcates into two primary effector pathways:
GIPR Signalling: Key Downstream Nodes
- PKA (Protein Kinase A) pathway: cAMP activates PKA holoenzyme by binding the regulatory subunits, releasing active catalytic subunits. PKA phosphorylates voltage-gated K+ channel subunits (Kv), components of the SNARE exocytotic machinery, and the transcription factor CREB — producing insulin secretion potentiation, gene expression changes related to beta cell survival and proliferation, and (in adipocytes) lipolytic enzyme regulation via HSL (hormone-sensitive lipase) phosphorylation.
- EPAC2 (Exchange Protein directly Activated by cAMP 2) pathway: EPAC2 is a guanine nucleotide exchange factor for the small GTPase Rap1. EPAC2/Rap1 activation contributes to insulin granule trafficking and exocytosis, independently of PKA. EPAC2 is particularly highly expressed in pancreatic beta cells, making this pathway especially relevant for GIPR and GLP-1R agonist research in islet biology contexts.
- PI3K/Akt cross-talk: GIPR activation has also been documented to activate phosphatidylinositol 3-kinase (PI3K) and Akt via downstream transactivation mechanisms — contributing to beta cell proliferation and survival signalling, and potentially to adipocyte metabolic regulation through Akt-mediated substrate phosphorylation.
- Beta-arrestin recruitment: Like GLP-1R, activated GIPR recruits beta-arrestin proteins that both desensitise the receptor (via internalisation) and initiate G protein-independent signalling cascades. Tirzepatide’s biased agonism profile at GIPR — which Willard et al. characterised as producing preferential cAMP signalling relative to beta-arrestin recruitment compared to native GIP — has research implications for the magnitude and duration of downstream cAMP-mediated effects.
The GLP-1 Receptor: Brief Recap and Link to Semaglutide Research
For researchers already familiar with GLP-1R biology — covered in depth in our semaglutide research guide — the key points for contextualising tirzepatide’s GLP-1R engagement are as follows:
GLP-1R is a class B1 GPCR expressed on pancreatic beta cells, cardiac muscle, vagal afferent neurons, brainstem nuclei (NTS, area postrema), hypothalamic neurons (arcuate, ventromedial), renal proximal tubule cells, and intestinal L-cells. GLP-1R signals primarily through Gαs/adenylyl cyclase/cAMP/PKA and EPAC pathways — the same effector axis as GIPR, but through a distinct receptor protein with its own expression pattern, ligand-binding domain, and desensitisation kinetics.
Tirzepatide engages GLP-1R as a partial agonist — it activates the receptor, but with lower intrinsic efficacy per molecule at GLP-1R than semaglutide (which is a full GLP-1R agonist). This is the “imbalanced” aspect of tirzepatide described in the Willard FS et al. (2020) title: it is biased toward GIPR, with partial rather than full GLP-1R agonism at the receptor level. In practice, tirzepatide achieves effective net GLP-1R signalling in vivo through its extended half-life and high steady-state plasma concentrations — sustained receptor occupancy compensates for lower intrinsic GLP-1R efficacy per binding event.
Why Dual Agonism Is Mechanistically Distinct: The Co-Activation Hypothesis
The central mechanistic hypothesis behind tirzepatide — and the reason it was developed rather than simply using a higher-dose GLP-1 agonist — is that simultaneous co-activation of two incretin receptors on the same cell produces intracellular signalling outputs that neither receptor can generate alone, even when each receptor’s individual contribution is at maximum saturation.
Beta Cell Co-Activation: Non-Redundant cAMP Pathways
In pancreatic beta cells, both GIPR and GLP-1R couple to Gαs and both elevate cAMP. This appears, at first glance, to be redundant — cAMP is cAMP. But the pharmacology is more nuanced. Published research has shown that GIPR and GLP-1R localise to distinct microdomains within the beta cell plasma membrane, and that their adenylyl cyclase coupling may engage different AC isoforms with different local cAMP dynamics. Furthermore, the spatiotemporal dynamics of cAMP elevation — where in the cell it peaks, how rapidly it rises, and how it is subsequently degraded by phosphodiesterases (PDEs) — can determine which downstream effectors are preferentially activated (PKA vs EPAC2) and what transcriptional targets are reached via CREB phosphorylation.
Willard FS et al. (2020, JCI Insight) characterised tirzepatide’s cell-based cAMP profile across both receptors and noted that it produces a pharmacodynamic signature distinct from either a GIP-only or GLP-1-only agonist — a published basis for the co-activation hypothesis that dual agonism generates a unique receptor engagement fingerprint in beta cells.
Complementary Peripheral Signalling
In adipose tissue, the lack of GLP-1R expression means that semaglutide has no direct adipocyte signalling mechanism — its effects on fat mass in research models are mediated primarily centrally (hypothalamic satiety signalling) and via gastric emptying delay. Tirzepatide, by contrast, has a direct GIPR-mediated adipocyte signalling pathway operating in parallel. Published research using selective GIPR agonists in adipocyte models has documented GIPR-mediated effects on lipid droplet metabolism, free fatty acid uptake, and lipoprotein lipase (LPL) regulation — mechanisms that create a distinct research dimension not present in GLP-1R-only agonist models.
The “Twincretin” Term in Academic Literature
The term “twincretin” was introduced in the academic literature specifically to distinguish tirzepatide-class dual GIPR/GLP-1R agonists from prior single-receptor incretin compounds. The term captures the conceptual innovation: rather than improving the pharmacokinetics or potency of an existing incretin agonist (the approach taken with semaglutide vs liraglutide), tirzepatide doubles the receptor targeting architecture — incorporating both incretin axes into a single peptide backbone. The Samms RJ et al. (2021, Cell Metabolism) paper “Functionally selective GIP receptor agonism” explored how the context of GIP receptor activation — in combination with GLP-1R co-activation versus alone — determines whether GIPR signalling produces qualitatively different metabolic outcomes. This is the mechanistic basis for the twincretin concept as it appears in metabolic research literature: the value is not just in having two receptors activated, but in having them co-activated simultaneously in the same tissue environment.
The GIP Paradox: Adipogenic vs Lipolytic Context-Dependence
The most scientifically interesting — and initially counterintuitive — aspect of tirzepatide’s research profile is how GIPR engagement in adipose tissue produces research outcomes that appear to contradict what was known about endogenous GIP. This is the “GIP paradox,” and it is one of the most actively discussed mechanistic questions in dual agonism literature.
Endogenous GIP, secreted postprandially from duodenal K-cells, was classically characterised as promoting adipose lipid storage. In fed states, GIP signalling in adipocytes enhances fatty acid uptake and triglyceride synthesis — a mechanism that made sense as part of the normal postprandial lipid disposition pathway (moving dietary fat into adipose storage after a meal). Early pharmacological thinking therefore concluded that GIPR agonism would worsen body composition in a research context.
The SURMOUNT and SURPASS trial data produced a finding that contradicted this expectation: tirzepatide, despite its GIPR agonism, produced greater body fat reduction in research participants than semaglutide at equivalent doses in the SURPASS-2 head-to-head — not less. Two explanatory mechanistic frameworks have been proposed in published literature:
- Central GIPR antagonism model: One hypothesis (explored in preclinical rodent work) is that hypothalamic GIPR activation by tirzepatide reduces food intake through a central mechanism that overrides the peripheral adipogenic signalling — the central effects dominating over peripheral ones at pharmacological GIPR occupancy levels.
- GLP-1R-dependent signalling switch model: Samms RJ et al. (2021) proposed that in the context of concurrent GLP-1R activation, the intracellular signalling environment within adipocytes (and other peripheral cells) is altered such that GIPR engagement produces lipolytic rather than lipogenic downstream effects. The co-activation creates a context in which GIPR signalling behaves differently than when GIPR is activated in isolation — a receptor crosstalk-dependent outcome that can only be observed in a dual agonist research model.
This paradox is precisely why tirzepatide is a scientifically distinct research tool from any single-receptor compound: the GIP paradox cannot be investigated with semaglutide (no GIPR signal), native GIP alone (no stable research compound, no GLP-1R context), or GIPR antagonists (which eliminate the signal entirely). Tirzepatide is the only available compound that provides GIPR co-activation in the GLP-1R-active context — making it irreplaceable for any research design that attempts to address the paradox mechanistically.
SURPASS Clinical Trial Programme: Overview and Mechanistic Interpretation
The SURPASS programme was a six-study Phase III clinical trial series conducted in populations with type 2 diabetes. The following is a mechanistic research overview of the programme’s structure and published data — referenced as historical scientific record, not as a therapeutic recommendation.
SURPASS-1 through SURPASS-6
- SURPASS-1: Tirzepatide 5mg, 10mg, 15mg vs placebo, 40 weeks, 478 participants with T2D on diet/exercise only. Established dose-response relationship and baseline safety profile.
- SURPASS-2: Tirzepatide (three doses) vs semaglutide 1mg, 1,879 participants, 40 weeks (Frias JP et al. 2021, NEJM). The pivotal head-to-head mechanistic comparison with GLP-1 mono-agonism. All three tirzepatide doses produced statistically greater HbA1c reduction and body weight change than semaglutide 1mg — providing the primary published evidence that dual agonism produces different research outcomes than GLP-1R-only agonism in matched human cohorts.
- SURPASS-3: Tirzepatide vs insulin degludec, 1,444 participants, 52 weeks. Research context: comparing dual incretin agonism against insulin replacement in insulin-naive T2D — mechanistically informative for insulin sensitisation and beta cell preservation hypotheses.
- SURPASS-4: Tirzepatide vs insulin glargine, 2,002 participants, 52 weeks, in T2D with high cardiovascular risk. Relevant for GIPR-mediated cardiovascular research hypotheses.
- SURPASS-5: Tirzepatide added to insulin glargine background, 475 participants, 40 weeks. Addresses the incremental GIPR/GLP-1R co-activation benefit over basal insulin.
- SURPASS-6: Tirzepatide vs semaglutide 1mg in insulin-experienced T2D patients, 1,428 participants. Extended the SURPASS-2 comparison to a population with more advanced disease background.
SURPASS-CVOT: Cardiovascular Research
The SURPASS cardiovascular outcomes trial (SURPASS-CVOT) evaluated tirzepatide against dulaglutide (a GLP-1 mono-agonist) in T2D patients with established cardiovascular disease or high cardiovascular risk. Published results (NEJM Evidence, 2024) documented tirzepatide’s cardiovascular outcomes profile against a GLP-1 mono-agonist active comparator — providing a mechanistically informative comparison for researchers investigating whether GIPR co-activation adds to or alters the cardiovascular research profile documented with GLP-1R mono-agonism. The GIPR’s documented expression in cardiac myocytes makes this a particularly relevant published dataset for cardiovascular biology researchers studying dual incretin receptor pharmacology.
SURMOUNT Clinical Trial Programme: Body Composition Research Context
The SURMOUNT programme evaluated tirzepatide in populations without type 2 diabetes — a research design that isolates the body composition and metabolic effects of dual GIPR/GLP-1R agonism from the confound of T2D-specific metabolic dysfunction.
SURMOUNT-1: The Landmark Publication
SURMOUNT-1 (Jastreboff AM et al. 2022, NEJM) enrolled 2,539 participants with BMI ≥27 kg/m² (with one or more weight-related comorbidity, excluding T2D) across 119 sites in nine countries. The trial ran for 72 weeks — one of the longest published Phase III body composition research trials at the time of publication. The 15mg tirzepatide dose arm produced a mean 20.9% body weight reduction from baseline versus 3.1% for placebo — the largest mean body weight reduction documented in any published Phase III trial for an incretin-class compound as of 2022. The mechanistic significance for research is in the lean mass preservation data: approximately 70% of the weight change was attributed to fat mass reduction and approximately 30% to lean mass change — a ratio broadly consistent with other GLP-1 class compounds in similar published research models, providing a baseline for comparing dual vs mono agonist effects on body composition composition.
SURMOUNT Programme Extension Studies
SURMOUNT-2 evaluated tirzepatide in participants with T2D (bridging the SURPASS and SURMOUNT datasets). SURMOUNT-3 examined tirzepatide after intensive lifestyle intervention — a design that contextualises dual agonism effects on weight maintenance after initial non-pharmacological intervention. SURMOUNT-4 investigated weight regain after tirzepatide discontinuation — providing published mechanistic data on the duration of GIPR/GLP-1R dual agonism dependence for sustained metabolic effects.
SURPASS-2: Mechanistic Interpretation of the Semaglutide Head-to-Head
The SURPASS-2 trial (Frias JP et al. 2021, NEJM) is the most directly relevant published dataset for any researcher attempting to isolate the mechanistic contribution of GIPR activation over GLP-1R-only agonism. Its design — tirzepatide (three doses) versus semaglutide 1mg weekly — provides a within-trial comparison between dual and mono incretin agonism at pharmacologically relevant doses.
The mechanistic interpretation framework for SURPASS-2 data should account for several variables:
- Dose equivalence is not receptor equivalence: Semaglutide 1mg weekly in SURPASS-2 is a high-efficacy GLP-1R full agonist dose — not a submaximal dose. The comparison is therefore between the full GLP-1R mono-agonist effect (semaglutide 1mg) and the dual GIPR/GLP-1R agonist effect (tirzepatide at each dose). Any difference in measured outcomes can be attributed to the addition of GIPR agonism (plus the partial vs full GLP-1R agonism distinction), not to GLP-1R under-dosing in the semaglutide arm.
- The comparator was active, not placebo: All differences reported are vs semaglutide 1mg, not vs placebo. This framing is important for research design: SURPASS-2 quantifies the incremental mechanistic contribution of GIPR co-activation over maximum practical GLP-1R mono-agonism — a particularly clean experimental question.
- Multiple mechanistic pathways contribute: The observed differences between tirzepatide and semaglutide arms in SURPASS-2 reflect the combined contribution of GIPR co-activation across all tissue compartments simultaneously — central GIPR satiety signalling, adipose GIPR metabolic effects, and beta cell GIPR/GLP-1R co-stimulation. The trial cannot isolate which tissue-specific GIPR mechanism drives which component of the observed difference — that mechanistic dissection is the work of subsequent preclinical and in vitro research.
GLP-1R Agonist Research Landscape: Mechanistic Comparison
| Parameter | Semaglutide (Ozempic/Wegovy) | Tirzepatide (Mounjaro) | Retatrutide |
|---|---|---|---|
| Receptor targets | GLP-1R only (mono-agonist) | GIPR + GLP-1R (dual agonist) | GIPR + GLP-1R + GCGR (triple agonist) |
| Agonism profile | Full GLP-1R agonist; unbiased | Full GIPR / partial GLP-1R; GIP-biased | Triple agonist with varying receptor bias by receptor type |
| Amino acid length | 31 aa (GLP-1 backbone) | 39 aa (GIP backbone) | 36 aa (GIP backbone) |
| Half-life | ~7 days (C18 fatty diacid, albumin binding) | ~5 days (C20 fatty diacid, albumin binding) | ~6 days (C18 fatty diacid, albumin binding) |
| CAS number | 910463-68-2 |
2023788-19-2 |
2381089-83-2 |
| Trial programme | SUSTAIN (1–10) + STEP (1–8) | SURPASS (1–6) + SURMOUNT (1–4) | TRIUMPH programme (Phase II/III, ongoing) |
| Head-to-head data | SURPASS-2 comparator (vs tirzepatide) | SURPASS-2 vs semaglutide 1mg (1,879 participants, 40 weeks) | Phase II TRIUMPH-1 data published (Jastreboff AM et al. 2023, NEJM) |
| Key mechanistic addition vs prior | Reference compound: GLP-1R benchmark | Adds GIPR axis — adipose, bone, CNS, beta cell GIPR co-activation | Adds glucagon receptor — hepatic gluconeogenesis suppression, lipolysis, additional energy expenditure pathway |
| UK regulatory status | POM — HMR 2012 | POM — HMR 2012 | POM — HMR 2012 |
| PGL research supply | Semaglutide 10mg — research only | Tirzepatide 10mg — research only | Retatrutide 10mg — research only |
Tirzepatide vs Retatrutide: The Next Step on the Incretin Agonism Spectrum
If tirzepatide represents dual agonism, retatrutide represents the next step: triple GIP/GLP-1/glucagon receptor (GCGR) agonism. Understanding why the glucagon receptor adds a mechanistically distinct research dimension requires understanding what GCGR activation does that GIPR and GLP-1R activation does not.
Glucagon is the primary counter-regulatory hormone to insulin — secreted from pancreatic alpha cells in response to hypoglycaemia, it drives hepatic gluconeogenesis and glycogenolysis to raise blood glucose. In pharmacological research contexts, however, GCGR agonism at supratherapeutic concentrations also produces lipolytic effects via hepatic and adipose GCGR signalling, increases energy expenditure through brown adipose tissue (BAT) thermogenic activation, and suppresses appetite via central GCGR pathways — effects that are distinct from and additive to GIPR and GLP-1R mechanisms.
The mechanistic architecture is therefore: semaglutide (GLP-1R only: central satiety + beta cell + gastric motility) → tirzepatide (adds GIPR: adipose, bone, CNS GIPR co-activation) → retatrutide (further adds GCGR: hepatic glucose output suppression, thermogenic energy expenditure, additional lipolysis). Each step adds a receptor with genuinely distinct tissue expression and intracellular signalling — producing a hierarchical research tool landscape where each compound provides a different mechanistic question it can address.
Retatrutide’s Phase II TRIUMPH-1 trial data (Jastreboff AM et al. 2023, NEJM) documented mean body weight reductions of up to 24.2% at 48 weeks — a published landmark for triple agonism in a Phase II context. The mechanistic interpretation of the additional effect vs tirzepatide involves isolating the GCGR contribution, which the triple vs dual comparison research design is specifically constructed to address.
UK POM Status and Research-Grade Supply Specifications
Tirzepatide holds prescription-only medicine (POM) status in the UK under the Human Medicines Regulations 2012. POM classification means the compound cannot be legally supplied as a medicinal product without a valid prescription from a registered prescriber. The research chemical supply route — under which Pure Grade Labs operates — is a legally distinct supply pathway for non-medicinal laboratory and preclinical research purposes, provided compounds are clearly designated as not for human use with explicit compliance labelling.
Researchers sourcing tirzepatide in the UK for laboratory purposes should confirm:
- Research intent is documented and the compound is used in appropriate laboratory conditions
- No human or animal administration outside of a licensed, ethically approved research protocol
- Compliance with all institutional and jurisdictional regulations governing research chemical procurement in the researcher’s context
Tirzepatide is not a controlled substance under the Misuse of Drugs Act 1971. Its research chemical supply is a lawful activity when conducted within the research chemical supply framework — distinct from pharmaceutical prescription supply.
Research-grade specifications (Pure Grade Labs):
- CAS:
2023788-19-2 - Molecular formula: C₂₂₅H₃₄₈N₄₈O₆₈
- Molecular weight:
4813.5 Da - Sequence: 39 amino acid dual GIP/GLP-1 receptor agonist with C20 fatty diacid albumin-binding moiety via glutamic acid-OEG-OEG linker
- Purity: ≥99% (HPLC verified) — batch-specific COA provided
- Vial format: Lyophilised powder, 10mg per vial
- Storage: -20°C, protected from light and moisture
A research group investigating the cellular basis of the GIP paradox in adipose tissue designs a three-arm in vitro study using primary human adipocytes. Their question: does GIPR activation in adipocytes produce qualitatively different intracellular signalling when GLP-1R is also co-activated on the same cell versus when GIPR is activated alone? And specifically — does the PKA/HSL axis (associated with lipolysis) or the PI3K/LPL axis (associated with lipid storage) dominate under each condition?
The experimental design requires three pharmacological conditions: (1) a selective GLP-1R agonist with no GIPR activity (semaglutide — providing pure GLP-1R signal as a baseline, noting that primary adipocytes express minimal GLP-1R, so GLP-1R’s direct adipocyte contribution is expected to be small), (2) a selective GIPR agonist in isolation (not commercially available in stable research-grade form without custom synthesis), and (3) a compound that co-activates both GIPR and GLP-1R simultaneously in the same cell — tirzepatide.
The logic: any difference between the GIPR-only signal and the GIPR + GLP-1R co-activation signal would be measurable by comparing a stable GIPR agonist against tirzepatide. But no stable, commercially available GIPR-selective agonist exists in research peptide format — native GIP has a plasma half-life of approximately 7 minutes, making controlled in vitro incubation impractical. Tirzepatide, with its C20 fatty acid albumin-binding design and Aib DPP-4 resistance, provides stable, sustained GIPR engagement in a cell culture system for up to 24 hours.
The researchers’ protocol is thus a comparison of arm (1) semaglutide — GLP-1R reference — against arm (3) tirzepatide — GIPR + GLP-1R co-activation — in primary adipocytes. Any downstream signalling difference between the two arms is attributable to the GIPR co-activation component, since tirzepatide’s GLP-1R engagement is equivalent or sub-equivalent to semaglutide’s. The finding — whether HSL phosphorylation (lipolysis) or LPL activity (lipid storage) is elevated under tirzepatide conditions relative to semaglutide — directly addresses the GIP paradox in a human adipocyte model.
This is the type of mechanistic research question for which tirzepatide’s unique dual receptor profile is not merely useful — it is irreplaceable. No other commercially available research compound provides stable GIPR + GLP-1R co-activation in a single molecule.
Frequently Asked Questions
What is tirzepatide and how does it relate to Mounjaro?
Tirzepatide is the active molecule — a synthetic 39-amino-acid dual GIP/GLP-1 receptor agonist with CAS number 2023788-19-2 and molecular weight 4813.5 Da. Mounjaro is the brand name under which Eli Lilly markets tirzepatide for specific metabolic indications in multiple jurisdictions, including the UK and EU. Zepbound is the US brand name for tirzepatide in a higher-dose formulation for a separate regulatory indication. The underlying molecule in all cases is identical. In the UK, tirzepatide (Mounjaro) is a prescription-only medicine under the Human Medicines Regulations 2012. Pure Grade Labs supplies tirzepatide strictly as a research chemical for laboratory purposes only — not for human consumption or any therapeutic use.
What makes tirzepatide a “dual agonist” and why does this matter for research?
Tirzepatide simultaneously activates two distinct G protein-coupled receptors — the GIP receptor (GIPR) and the GLP-1 receptor (GLP-1R). It was engineered on a GIP peptide backbone with a C20 fatty diacid albumin-binding moiety, and behaves as a full agonist at GIPR and a partial agonist at GLP-1R (GIP-biased dual agonism). This dual receptor profile matters for research because GIPR and GLP-1R have non-identical tissue expression patterns, non-redundant intracellular signalling pathways, and access different peripheral tissue compartments — particularly adipose tissue (GIPR expressed, GLP-1R minimally expressed) and bone (GIPR expressed, GLP-1R not significantly expressed). Any research question involving GIPR biology, GIPR/GLP-1R receptor crosstalk, or the GIP paradox in adipose tissue requires a compound that activates GIPR — which semaglutide (GLP-1 mono-agonist) cannot do. Tirzepatide is the only commercially available research-grade compound that provides stable, equipotent GIPR/GLP-1R co-activation in a single molecule.
How does tirzepatide compare to semaglutide mechanistically?
The core mechanistic difference is receptor targeting architecture. Semaglutide is a GLP-1R mono-agonist — it activates only the GLP-1R, with high intrinsic efficacy (full agonism). Tirzepatide is a dual GIP/GLP-1R agonist — it activates both GIPR (full agonism) and GLP-1R (partial agonism, GIP-biased). At the GLP-1R level, tirzepatide has lower intrinsic efficacy per binding event than semaglutide — but achieves effective net GLP-1R signal through its extended half-life and sustained receptor occupancy. Beyond the receptor level, tirzepatide adds GIPR-mediated signalling in adipose tissue, bone, and additional CNS nuclei — mechanisms with no equivalent in semaglutide research models. The SURPASS-2 head-to-head trial (1,879 participants, 40 weeks) published in the NEJM (Frias JP et al. 2021) provides the primary clinical research dataset for the measurable differences in metabolic parameters between the two compounds in matched human cohorts. The difference is mechanistically attributed to GIPR co-activation and the complementary dual receptor signalling architecture.
What did the SURMOUNT clinical trials find?
The SURMOUNT programme was a four-study Phase III clinical trial series evaluating tirzepatide in populations without type 2 diabetes. SURMOUNT-1 (Jastreboff AM et al. 2022, NEJM) is the landmark publication: 2,539 participants, BMI ≥27 kg/m² with comorbidity excluding T2D, randomised to tirzepatide 5mg, 10mg, 15mg weekly or placebo, followed for 72 weeks across 119 sites in nine countries. The 15mg dose arm produced a mean 20.9% body weight reduction from baseline vs 3.1% for placebo — at the time, the largest mean body weight reduction documented in any published Phase III trial for an incretin-class compound. Lean mass vs fat mass composition of the body weight change was assessed: approximately 70% attributed to fat mass and 30% to lean mass — providing reference data for GIPR/GLP-1R dual agonism effects on body composition research outcomes in a non-diabetic cohort. SURMOUNT-2, -3, and -4 extended the programme into T2D populations, maintenance design, and post-discontinuation relapse research respectively. All publications are indexed on PubMed and available through their respective journal publishers.
Is tirzepatide legal in the UK? Can it be sourced as a research chemical?
Tirzepatide is a prescription-only medicine (POM) in the UK under the Human Medicines Regulations 2012 — meaning it cannot be supplied as a medicinal product for human administration without a valid prescription from a registered prescriber. However, tirzepatide is not a controlled substance under the Misuse of Drugs Act 1971. It can be lawfully supplied and procured in the UK as a research chemical for laboratory and preclinical research purposes, provided it is clearly designated as not for human use. Pure Grade Labs supplies tirzepatide 10mg strictly within this research chemical framework — with explicit compliance labelling, batch-specific HPLC certificate of analysis, and no implication of human use. Researchers must ensure their procurement and use complies with all applicable institutional and jurisdictional regulations in their context.
Summary
Tirzepatide (Mounjaro) is mechanistically distinct from any prior incretin compound not because it does what semaglutide does more efficiently — but because it opens a receptor axis that GLP-1 mono-agonism cannot access. The GIP receptor’s expression in adipose tissue, bone, cardiac muscle, and specific CNS nuclei creates a peripheral pharmacology that is absent from all GLP-1R-only research models. The “twincretin” architecture — GIPR full agonism combined with GLP-1R partial agonism in a single C20 fatty diacid-extended peptide — produces intracellular signalling in pancreatic beta cells, adipocytes, and central neurons that published research has characterised as qualitatively distinct from either receptor alone (Willard FS et al. 2020, JCI Insight; Samms RJ et al. 2021, Cell Metabolism).
The GIP paradox — where a receptor classically associated with adipogenic signalling appears to facilitate a different metabolic outcome in the context of GLP-1R co-activation — is arguably the most scientifically interesting unresolved question in dual agonism research, and tirzepatide is the only available compound that allows it to be investigated in a single-molecule model. The SURPASS and SURMOUNT trial programmes have produced one of the largest published clinical research datasets for any incretin-class compound, culminating in the SURPASS-2 head-to-head vs semaglutide 1mg (1,879 participants, 40 weeks) as the primary published benchmark for dual vs mono incretin agonism in human cohorts.
On the incretin agonism research spectrum — semaglutide (GLP-1 mono) → tirzepatide (dual GIP + GLP-1) → retatrutide (triple GIP + GLP-1 + glucagon) — tirzepatide occupies the mechanistically pivotal middle position: the first compound to validate dual incretin co-activation in Phase III clinical research, and the reference point against which triple agonism research is now compared.
For UK laboratory researchers, tirzepatide 10mg is available from Pure Grade Labs as an HPLC-verified research chemical with batch-specific COA. For comparative incretin agonism studies, the Metabolic Research Stack bundles tirzepatide and semaglutide together.
References
- Willard FS, Douros JD, Gabe MBN, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020;5(12):e140532. doi:10.1172/jci.insight.140532
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205–216. doi:10.1056/NEJMoa2206038
- Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). N Engl J Med. 2021;385(6):503–515. doi:10.1056/NEJMoa2107519
- Samms RJ, Coghlan MP, Sloop KW. How may GIP enhance the therapeutic efficacy of GLP-1? Trends Endocrinol Metab. 2020;31(6):410–421. doi:10.1016/j.tem.2020.02.006 [Functionally selective GIP receptor agonism context]
- Samms RJ, Christe ME, Collins KA, et al. GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice. J Clin Invest. 2021;131(12):e146353. doi:10.1172/JCI146353
- Coskun T, Urva S, Roell WC, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Mol Metab. 2022;57:101427. doi:10.1016/j.molmet.2022.101427
- Zhong Q, Itokawa T, Sridhar S, et al. Effects of glucose-dependent insulinotropic peptide on osteoclast function. Am J Physiol Endocrinol Metab. 2007;292(2):E543–548. doi:10.1152/ajpendo.00364.2006
- Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial (TRIUMPH-1). N Engl J Med. 2023;389(6):514–526. doi:10.1056/NEJMoa2301972